For example, midostaurin—a small molecule inhibitor of the receptor Fms Related Receptor Tyrosine Kinase 3 (FLT3) that also targets other kinases—was approved in 2017 to treat acute myeloid leukemia (AML) patients positive for FLT3 mutations, even though >40% of FLT3 mutant-positive AML patients fail to respond to midostaurin12 and >30% of FLT3 mutant negative could potentially benefit from treatment13. Here, FLT3 is linked to acute myeloid leukemia.